---
document_datetime: 2023-09-21 20:32:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/zercepac-epar-all-authorised-presentations_en.pdf
document_name: zercepac-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7997616
conversion_datetime: 2025-12-27 21:07:08.311104
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                              | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|--------------------------------------------------|---------------------------|-----------------------|-------------|
| EU/1/20/1456/001 | Zercepac          | 150 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial      |
| EU/1/20/1456/002 | Zercepac          | 60 mg      | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial      |
| EU/1/20/1456/003 | Zercepac          | 420 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial      |